Back to top

Image: Bigstock

HCA Holdings Boosts Patient Care; to Buy Mobile Heartbeat

Read MoreHide Full Article

HCA Holdings Inc. (HCA - Free Report) recently inked a deal to buy Mobile Heartbeat for an undisclosed amount. The transaction is expected to be closed by the end of 2016. Upon completion, Mobile Heartbeat will become an indirect wholly owned subsidiary of HCA Holdings and will be led by its present chief executive officer, Ron Remy.

Mobile Heartbeat is a leading developer of smartphone applications to improve clinical workflow and team communications. Its technology solutions integrate clinical communications like alarms and notifications, patient information and lab data, secure texting, voice and photography. The company has always worked toward addressing the mobile technology demand of clinicians.

HCA  Holdings recently concluded the trial of Mobile Heartbeat’s CURE (Clinical Urgent Response) technology for its iMobile Project. This project focuses on implementation of smartphone-based critical care team communications. Following the success of the pilot program, HCA launched Mobile Heartbeat’s CURE technology across its 21 hospitals. The company now intends to implement the technology enterprise-wide.

HCA Holdings, which operates 169 hospitals and 116 freestanding surgery centers in 20 states and the U.K., believes that adding Mobile Heartbeat will help it to enhance patient care by improving clinical workflows and providing secure communications. The company is committed to providing seamless care to its patients and will thus, benefit from the acquisition of Mobile Heartbeat.

On the other hand, Mobile Heartbeat stands to gain from its association with HCA Holding – one of the leading healthcare providers in the world.

Zacks Rank and Stocks to Consider

HCA Holdings presently carries Zacks Rank #3 (Hold). Some better-ranked stocks in the medical sector are The Advisory Board Company , Actelion Ltd. and Amphastar Pharmaceuticals, Inc. (AMPH - Free Report) . Each of these stocks sports Zacks Rank #1 (Strong Buy).

Confidential from ZacksBeyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


Unique Zacks Analysis of Your Chosen Ticker


Pick one free report - opportunity may be withdrawn at any time


Amphastar Pharmaceuticals, Inc. (AMPH) - $25 value - yours FREE >>

HCA Healthcare, Inc. (HCA) - $25 value - yours FREE >>

Published in